Dongin (Donoven) Kim, Ph.D.

---

Publications & Presentations

26. Siefert A L, Fahmy T M, Kim D. Artificial Antigen-Presenting Cells for Immunotherapies. Methods in molecular biology (Clifton, N.J.). 2017; 1530 : 343-353

27. Youm Y H, Nguyen K Y, Grant R W, Goldberg E L, Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti T D, Kang S, Horvath T L, Fahmy T M, Crawford P A, Biragyn A, Alnemri E, Dixit V D. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nature medicine. 2015; 21 : 263-9

28. Yim H, Park W, Kim D, Fahmy T M, Na K. A self-assembled polymeric micellar immunomodulator for cancer treatment based on cationic amphiphilic polymers. Biomaterials. 2014; 35 : 9912-9919

29. Lee J O, Oh K T, Kim D, Lee E S. pH-sensitive short worm-like micelles targeting tumors based on the extracellular pH. Journal of materials chemistry. B. 2014; 2 : 6363-6370

30. Lee U Y, Oh Y T, Kim D, Lee E S. Multimeric grain-marked micelles for highly efficient photodynamic therapy and magnetic resonance imaging of tumors. International journal of pharmaceutics. 2014; 471 : 166-72

Grants

1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.

2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.

3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.

5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

Awards and Honors

no results

Education

1. Degree: Ph D. University of Utah. Date: 2009.


2. Degree: MS. University of Florida. Date: 2002.


3. Degree: BS. Ajou University. Date: 1999.

Administrative Assignments

no results